• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by National Research Corporation (Amendment)

    2/13/24 4:05:33 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email
    SC 13G/A 1 fp0086862-61_sc13ga.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 8)*

     

    NATIONAL RESEARCH CORP

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    637372202

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X] Rule 13d-1(b)

    [  ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 637372202   13G   Page 2 of 10 Pages

     

    1.

    NAMES OF REPORTING PERSONS OR

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Kayne Anderson Rudnick Investment Management, LLC

    95-4575414

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) [ ]

    (b) [ ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    A California Limited Liability Company

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    456,647

    6.

    SHARED VOTING POWER

     

    2,388,917

    7.

    SOLE DISPOSITIVE POWER

     

    492,608

    8.

    SHARED DISPOSITIVE POWER

     

    2,388,917

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,881,525

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [ ]

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    11.73%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

     

     

     

    CUSIP No. 637372202   13G   Page 3 of 10 Pages

     

    1.

    NAMES OF REPORTING PERSONS OR

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Virtus Investment Advisers, Inc.

    04-2453743

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) [ ]

    (b) [ ]

    3. SEC USE ONLY  
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Massachusetts

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,388,917

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    2,388,917

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,388,917

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [ ]

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.73%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

     

     

    FOOTNOTES - The amounts reported on this page are also included in the amounts reported by Kayne Anderson Rudnick Investment Management, LLC on this Schedule 13G.

     

     

    CUSIP No. 637372202   13G   Page 4 of 10 Pages

     

    1.

    NAMES OF REPORTING PERSONS OR

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) [ ]

    (b) [ ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,109,518

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    2,109,518

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,109,518

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [ ]

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.59%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IV

     

     

    FOOTNOTES - The amounts reported on this page are also included in the amounts reported by Virtus Investment Advisers, Inc. on this Schedule 13G.

     

     

    CUSIP No. 637372202   13G   Page 5 of 10 Pages

     

    Item 1. (a)

    Name of Issuer

    NATIONAL RESEARCH CORP

         
      (b)

    Address of Issuer’s Principal Executive Offices

    1245 Q Street, Lincoln, NE 68508

     

    Item 2. (a)

    Name of Person Filing

    (1)  Kayne Anderson Rudnick Investment Management, LLC

    (2)  Virtus Investment Advisers, Inc.

    (3)  Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund

         
      (b)

    Address of the Principal Office or, if none, residence

    (1)  Kayne Anderson Rudnick Investment Management, LLC

    2000 Avenue of the Stars, Suite 1110, Los Angeles, CA 90067

    (2)  Virtus Investment Advisers, Inc.

    One Financial Plaza, Hartford, CT 06103

    (3)  Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund

    101 Munson Street, Greenfield, MA 01301

         
      (c)

    Citizenship

    (1)  Kayne Anderson Rudnick Investment Management, LLC: A California Limited Liability Company

    (2)  Virtus Investment Advisers, Inc.: Massachusetts

    (3)  Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund: Delaware

         
      (d)

    Title of Class of Securities

    Common Stock

         
      (e)

    CUSIP Number

    637372202

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [X] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

    CUSIP No. 637372202   13G   Page 7 of 10 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount beneficially owned:

    (1)  Kayne Anderson Rudnick Investment Management LLC:

    (2)  Virtus Investment Advisers, Inc.:

    (3)  Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund:

     

    2,881,525

    2,388,917

    2,109,518

    (b)

    Percent of class:

    (1)  Kayne Anderson Rudnick Investment Management LLC:

    (2)  Virtus Investment Advisers, Inc.:

    (3)  Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund:

     

    11.73%

    9.73%

    8.59%

    (c) Number of shares as to which the person has:  
      (i)

    Sole power to vote or to direct the vote:

    (1)  Kayne Anderson Rudnick Investment Management LLC:

    (2)  Virtus Investment Advisers, Inc.:

    (3)  Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund:

     

    456,647

    0

    0

      (ii)

    Shared power to vote or to direct the vote:

    (1)  Kayne Anderson Rudnick Investment Management LLC:

    (2)  Virtus Investment Advisers, Inc.:

    (3)  Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund:

     

    2,388,917

    2,388,917

    2,109,518

      (iii)

    Sole power to dispose or to direct the disposition of:

    (1)  Kayne Anderson Rudnick Investment Management LLC:

    (2)  Virtus Investment Advisers, Inc.:

    (3)  Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund:

     

    492,608

    0

    0

      (iv) Shared power to dispose or to direct the disposition of:  
       

    (1)  Kayne Anderson Rudnick Investment Management LLC:

    (2)  Virtus Investment Advisers, Inc.:

    (3)  Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund:

    2,388,917

    2,388,917

    2,109,518

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ] .

    Instruction. Dissolution of a group requires a response to this item.

     

    N/A

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    With respect to securities owned by a registered investment company included in this filing, only the custodian for such investment company, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of such investment company participate proportionately in any dividends and distributions so paid.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    N/A

     

     

    CUSIP No. 637372202   13G   Page 9 of 10 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Kayne Anderson Rudnick Investment Management, LLC
       
      By: /s/ Michael Shoemaker
      Name: Michael Shoemaker
      Title: Chief Compliance Officer
      Date: February 13, 2024
       
      Virtus Investment Advisers, Inc.
       
      By: /s/ David Fusco
      Name:   David Fusco
      Title: Vice President and Chief Compliance Officer
      Date: February 13, 2024
       
      Virtus Equity Trust on behalf of Virtus KAR Small Cap Growth Fund
       
      By: /s/ Daphne Chisolm
      Name: Daphne Chisolm
      Title: Vice President, Counsel and Assistant Secretary
      Date: February 13, 2024

     

    Get the next $NRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    SEC Filings

    See more
    • National Research Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/12/25 9:01:47 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by National Research Corporation

      10-Q - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/9/25 10:02:32 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      4/28/25 5:12:02 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Bhandari Parul

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/9/25 5:11:12 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Wheeler Penny Ann

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/9/25 5:09:46 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Financials

    Live finance-specific insights

    See more

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Announces Fourth Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $36.9 million compared with approximately $38.0 million in the 2023 quarter. Earnings per diluted share were $0.28 compared with $0.36 for the 2023 quarter. At December 31, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) was approximately $58.5 million. Total recurring contract value (TRCV) was approximately $133.2 million at December 31, 2024. Dividends and Stock Repurchases During the quarter, the Company returned approximately $10.1 millio

      1/27/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • A New Era of Trust: NRC Health's 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience

      NRC Health unveils its 2025 Experience Perspective Report, highlighting new research and trends shaping the future of healthcare, with a focus on trust, generational shifts, and evolving consumer demands. NRC Health, a recognized leader in healthcare experience management solutions to transform interactions for patients, consumers, and employees alike, released its 2025 Experience Perspective today during a live national webcast. Known for delivering premier market research and data-driven insights, NRC Health's report features key findings and strategic recommendations based on extensive research involving millions of consumers, patients, and other healthcare leaders nationwide. Guided b

      4/10/25 2:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Research Corporation

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      11/13/24 4:05:19 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by National Research Corporation (Amendment)

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/8/24 4:05:05 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by National Research Corporation (Amendment)

      SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/5/24 4:31:31 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    See more
    • National Research Corporation Appoints Trent Green as Chief Executive Officer

      National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

      3/4/25 4:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer

      Baron will align and advance NRC Health's experience solutions platform to solve health care industry challenges and continue effectively innovating and supporting experience improvement for health systems across the nation. NRC Health, a recognized leader providing solutions and data driven insights for improving health care experiences, announced today the appointment of Jennifer Baron as the organization's first chief experience officer. Baron's addition is part of the organization's continued investments in leadership and innovation to align with the evolving healthcare landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho

      4/2/24 11:55:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions

      NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions. The strategic move will allow NRC Health to accelerate innovation while continuing to provide exceptional customer experiences to its partners. Four newly created executive leadership roles will guide NRC Health's strategy and success, including: Helen Hrdy, Chief Customer Officer Jason Hahn, Chief Revenue Officer Christophe Louvion, Chief Product Technology Officer Andy Monnich, Chief Corporate Development Officer "Strong leadership is key in driving innovation and meeting the ever-evolv

      2/1/24 10:00:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care